Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AbbVie, Jazz Pharmaceuticals, and Servier Pharmaceuticals LLC
Description:
Acute myeloid leukemia (AML) is a cancer of the myeloid line of
blood cells, characterized by the rapid growth of abnormal white
blood cells that build up in the bone marrow and interfere with the
production of normal blood cells. AML is the most common acute
leukemia affecting adults, and its incidence increases with age.
Although AML is a relatively rare disease, accounting for roughly
1.2% of cancer deaths in the United States, its incidence is
expected to increase as the population ages. The American Cancer
Society estimates that there were approximately 20,050 new cases of
AML and 11,540 deaths from AML in the United States in 2022. The
five-year survival rate has not improved in older patients despite
40 years of research. Fortunately for patients with AML, many new
treatments are now here. New options, which have the ability to
target certain types of mutations, have been approved in AML for the
first time since 1990. With so many new options becoming available
in the past few years, the treatment paradigm in AML, especially in
relapsed or refractory and high-risk disease and in maintenance
settings, has drastically changed. With that change comes a
knowledge gap among physician medical directors, oncologists,
practicing physicians and nurses. For this reason, it is critical
that these HCPs are educated and updated on these emerging options
and strategies for their implementation into the treatment paradigm,
which will ultimately improve patient outcomes in the AML patient
population.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic
burden of AML, including factors that contribute to poor
prognosis and increased costs
-
Outline the role of molecular
alterations and cytogenetic testing for risk stratification and
treatment planning in AML
-
Analyze recent data on the efficacy
and safety of novel therapeutics in AML, including newer
targeted, cytotoxic, and antibody-based strategies, in a range
of patient populations
-
Summarize clinical,
molecular/genetic, and pathologic features of secondary AML and
cite efficacy and safety evidence surrounding the use of novel
therapeutics in these patients
-
Explore the evolving role of oral
IDH1 inhibitors in patients with AML with an IDH1 mutation,
including newer combination options
-
Employ interventions such as
clinical pathways and site of care initiatives for optimal cost
management and improved outcomes in AML, including secondary AML
|
Faculty: |
Jeffrey E. Lancet, MD
Chair, Dept of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Lancet has served as a consultant for AbbVie,
Bristol Myers Squibb, Jasper Therapeutics, Jazz
Pharmaceuticals, Novartis, and Servier. His presentation
has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AbbVie, Jazz Pharmaceuticals, and Servier Pharmaceuticals LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |